STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion

Cancer Discovery

Volumn 6, Issue 4, 2016, Pages 414-429

  Gotthardt, Dagmar ^a   Putz, Eva M ^a,f   Grundschober, Eva ^a   Prchal Murphy, Michaela ^a   Straka, Elisabeth ^a   Kudweis, Petra ^a   Heller, Gerwin ^b   Bago Horvath, Zsuzsanna ^b   Witalisz Siepracka, Agnieszka ^a   Cumaraswamy, Abbarna A ^c   Gunning, Patrick T ^c   Strobl, Birgit ^a   Müller, Mathias ^a   Moriggl, Richard ^a,d   Stockmann, Christian ^e   Sexl, Veronika ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TORONTO   (Canada)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; GAMMA INTERFERON; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT5 PROTEIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; HUMAN; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR PROMOTION; ANIMAL; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION; CYTOLOGY; CYTOTOXICITY; DEFICIENCY; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENE INACTIVATION; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; MOUSE; NEOPLASM; PATHOLOGY; SECRETION (PROCESS); TRANSGENIC MOUSE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT5 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962430593     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0732     Document Type: Article

References (51)

1. Spits H, Artis D, Colonna M, Diefenbach A, Santo JP Di, Eberl G, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-9.
2. Shi F-D, Ljunggren H-G, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011: 658-71.
3. Gotthardt D, Prchal-Murphy M, Seillet C, Glasner A, Mandelboim O, Carotta S, et al. NK cell development in bone marrow and liver: Site matters. Genes Immun 2014; 15: 584-7.
4. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12: 1065-74.
5. Di Santo JP. Natural killer cell developmental pathways: A question of balance. Annu Rev Immunol 2006; 24: 257-86.
6. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol 2000; 37: 1-11.
7. Levy DE, Darnell JE. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-62.
8. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK cell survival and development. Blood 2011; 117: 1565-73.
9. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22: 711-21.
10. Berger A, Sexl V, Valent P, Moriggl R. Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. Oncotarget 2014; 5: 9564-76.
11. Bandapalli OR, Schuessele S, Kunz JB, Rausch T, Stutz AM, Tal N, et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica 2014; 99: e188-92.
12. Kucuk C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from mmmm-T or NK cells. Nat Commun 2015; 6: 6025.
13. Debierre-Grockiego F. Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies. Apoptosis 2004; 9: 717-28.
14. Aichberger KJ, Mayerhofer M, Krauth M-T, Skvara H, Florian S, Sonneck K, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-11.
15. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000; 96: 2269-76.
16. Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan A-S, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget 2012; 3: 1669-87.
17. Malin S, Mcmanus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P, et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2009; 11: 171-9.
18. Kim S, Iizuka K, Kang H-SPS, Dokun A, French AR, Greco S, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 2002; 3: 523-8.
19. Hayakawa Y, Huntington ND, Nutt SL, Smyth MJ. Functional subsets of mouse natural killer cells. Immunol Rev 2006; 214: 47-55.
20. Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin M, Vandenberg CJ, et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun 2014; 5: 4539.
21. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999; 10: 249-59.
22. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2010; 2: 98-110.
23. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42: 501-10.
24. Gotthardt D, Putz EM, Straka E, Kudweis P, Biaggio M, Poli V, et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 2014; 124: 2370-9.
25. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep 2013; 1-8.
26. Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114: 1650-8.
27. Wallin RPA, Screpanti V, Michaelsson J, Grandien A, Ljunggren HG. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol 2003; 33: 2727-35.
28. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383-95.
29. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009; 1796: 11-8.
30. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014; 5: 1-13.
31. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008: 711-21.
32. Zhang J, Scordi I, Smyth MJ, Lichtenheld MG. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med 1999; 190: 1297-308.
33. Bruno A, Focaccetti C, Pagani A, Imperatori AS, Spagnoletti M, Rotolo N, et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 2013; 15: 133-42.
34. Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, et al. Characterization of tumor infiltrating natural killer cell subset. Oncotarget 2015; 6: 13835-43.
35. Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/ TANKs: Tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst 2014; 106: dju200.
36. Cerdeira AS, Rajakumar A, Royle CM, Lo A, Husain Z, Thadhani RI, et al. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol 2013; 190: 3939-48.
37. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-27.
38. Schonberg K, Rudolph J, Vonnahme M, Parampalli S, Cornez I, Hejazi M, et al. JAK inhibition impairs NK cell function. Cancer Res 2015; 75: 2187-99.
39. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27: 16-25.
40. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 93: 1612-21.
41. Gerber H, Hillan K, Ryan A, Kowalski J. VEGF is required for growth and survival in neonatal mice. Apoptosis 1999; 1159: 1149-59.
42. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-9.
43. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams J M. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A 1999; 96: 14943-8.
44. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-86.
45. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997; 94: 7239-44.
46. Cumaraswamy AA, Lewis AM, Geletu M, Todic A, Diaz DB, Cheng XR, et al. Nanomolar-potency small molecule inhibitor of STAT5 protein. ACS Med Chem Lett 2014; 5: 1202-6.
47. Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 2012; 1: 1027-37.
48. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting K D, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl-and bcr/abl-induced transformation are independent of Stat5. Blood 2000; 96: 2277-83.
49. Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, et al. Loss of STAT3 in lymphoma relaxes NK cell-mediated tumor surveillance. Cancers (Basel) 2014; 6: 193-210.
50. Pathria P, Gotthardt D, Prchal-Murphy M, Putz E-M, Holcmann M, Schlederer M, et al. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology 2015; 4: e998529.
51. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res 2015; 43(W1): W566-70. PubMed PMID: 25969447. Pubmed Central PMCID: 4489295.